Higher lorazepam doses may be riskier for seniors with weak kidneys

NCT ID NCT07179978

Completed Knowledge-focused Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at over 12,000 older adults (66+) with low kidney function who started taking lorazepam. Researchers compared higher doses (1-4 mg/day) to lower doses (0.5-1 mg/day) to see if there was a greater risk of hospitalization, emergency visits, or death within 30 days. The goal is to understand safe prescribing for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorazepam
What this could lead to: If it succeeds, this could help doctors prescribe safer lorazepam doses for older adults with kidney problems, reducing hospital visits and deaths.
What could go wrong: This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (CKD)

Contacts and locations

Locations

London Health Sciences Centre Research Institute

London, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.